BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. 1996

A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
Department of Anesthesiology and Critical Care Medicine, University of Pittsburgh School of Medicine, PA, USA.

We determined the pharmacokinetics and pharmacodynamics of cisatracurium, one of the 10 isomers of atracurium, in 14 patients with end-stage liver disease undergoing liver transplantation and in 11 control patients with normal hepatic and renal function undergoing elective surgery. Blood samples were collected for 8 h after i.v. bolus administration of cisatracurium 0.1 mg kg-1 (2 x ED95). Plasma concentrations of cisatracurium and its metabolites were determined using an HPLC method with fluorescence detection. Pharmacokinetic variables were determined using non-compartmental methods. Neuromuscular block was assessed by measuring the electromyographic evoked response of the adductor pollicis muscle to train-of-four stimulation of the ulnar nerve using a Puritan-Bennett Datex (Helsinki, Finland) monitor. Pharmacodynamic modelling was completed using semi-parametric effect-compartment analysis. Volume of distribution at steady state was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients (P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7 (0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4 (2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns). The time to maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery) was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in control patients (ns). The recovery index (25-75% recovery) was also similar in both groups: 15.4 (4.2) min in liver transplant patients and 12.8 (1.9) min in control patients (ns). After cisatracurium, peak laudanosine concentrations were 16 (5) and 21 (5) ng ml-1 in liver transplant and control patients, respectively. In summary, minor differences in the pharmacokinetics and pharmacodynamics of cisatracurium in liver transplant and control patients were not associated with any clinically significant differences in recovery profiles after a single dose of cisatracurium.

UI MeSH Term Description Entries
D007536 Isomerism The phenomenon whereby certain chemical compounds have structures that are different although the compounds possess the same elemental composition. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Isomerisms
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009469 Neuromuscular Junction The synapse between a neuron and a muscle. Myoneural Junction,Nerve-Muscle Preparation,Junction, Myoneural,Junction, Neuromuscular,Junctions, Myoneural,Junctions, Neuromuscular,Myoneural Junctions,Nerve Muscle Preparation,Nerve-Muscle Preparations,Neuromuscular Junctions,Preparation, Nerve-Muscle,Preparations, Nerve-Muscle
D003473 Neuromuscular Nondepolarizing Agents Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarization of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anesthesia adjuvants. Curare-Like Agents,Curariform Drugs,Muscle Relaxants, Non-Depolarizing,Neuromuscular Blocking Agents, Competitive,Nondepolarizing Blockers,Agents, Curare-Like,Agents, Neuromuscular Nondepolarizing,Blockers, Nondepolarizing,Curare Like Agents,Drugs, Curariform,Muscle Relaxants, Non Depolarizing,Non-Depolarizing Muscle Relaxants,Nondepolarizing Agents, Neuromuscular
D005071 Evoked Potentials Electrical responses recorded from nerve, muscle, SENSORY RECEPTOR, or area of the CENTRAL NERVOUS SYSTEM following stimulation. They range from less than a microvolt to several microvolts. The evoked potential can be auditory (EVOKED POTENTIALS, AUDITORY), somatosensory (EVOKED POTENTIALS, SOMATOSENSORY), visual (EVOKED POTENTIALS, VISUAL), or motor (EVOKED POTENTIALS, MOTOR), or other modalities that have been reported. Event Related Potential,Event-Related Potentials,Evoked Potential,N100 Evoked Potential,P50 Evoked Potential,N1 Wave,N100 Evoked Potentials,N2 Wave,N200 Evoked Potentials,N3 Wave,N300 Evoked Potentials,N4 Wave,N400 Evoked Potentials,P2 Wave,P200 Evoked Potentials,P50 Evoked Potentials,P50 Wave,P600 Evoked Potentials,Potentials, Event-Related,Event Related Potentials,Event-Related Potential,Evoked Potential, N100,Evoked Potential, N200,Evoked Potential, N300,Evoked Potential, N400,Evoked Potential, P200,Evoked Potential, P50,Evoked Potential, P600,Evoked Potentials, N100,Evoked Potentials, N200,Evoked Potentials, N300,Evoked Potentials, N400,Evoked Potentials, P200,Evoked Potentials, P50,Evoked Potentials, P600,N1 Waves,N2 Waves,N200 Evoked Potential,N3 Waves,N300 Evoked Potential,N4 Waves,N400 Evoked Potential,P2 Waves,P200 Evoked Potential,P50 Waves,P600 Evoked Potential,Potential, Event Related,Potential, Event-Related,Potential, Evoked,Potentials, Event Related,Potentials, Evoked,Potentials, N400 Evoked,Related Potential, Event,Related Potentials, Event,Wave, N1,Wave, N2,Wave, N3,Wave, N4,Wave, P2,Wave, P50,Waves, N1,Waves, N2,Waves, N3,Waves, N4,Waves, P2,Waves, P50
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
Pharmacokinetics and pharmacodynamics of cisatracurium in patients undergoing surgery with two hemodilution methods.
May 2017, Journal of clinical anesthesia,
A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation.
January 1989, Mayo Clinic proceedings,
A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
The management of perioperative nutrition in patients with end stage liver disease undergoing liver transplantation.
October 2015, Hepatobiliary surgery and nutrition,
A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
Pharmacodynamics and pharmacokinetics of cisatracurium in geriatric surgical patients.
March 1996, Anesthesiology,
A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
Significance of sarcopenia in children with end-stage liver disease undergoing liver transplantation.
August 2021, Pediatric transplantation,
A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease.
January 1988, Clinical pharmacology and therapeutics,
A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
Altered Cisatracurium Pharmacokinetics and Pharmacodynamics in Patients with Congenital Heart Defects.
January 2016, Drug metabolism and disposition: the biological fate of chemicals,
A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.
October 2012, Clinical pharmacokinetics,
A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease.
September 2010, Clinical journal of the American Society of Nephrology : CJASN,
A M De Wolf, and J A Freeman, and V L Scott, and W Tullock, and D A Smith, and D F Kisor, and S Kerls, and D R Cook
Pharmacokinetics and pharmacodynamics of thiopental in patients undergoing renal transplantation.
December 1983, Acta anaesthesiologica Scandinavica,
Copied contents to your clipboard!